This brand name is authorized in Nigeria.
The drug AQUACLAV contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
804826J2HU - AMOXICILLIN
|
|
Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bactericidal peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death. |
|
2
|
UNII
Q42OMW3AT8 - CLAVULANATE POTASSIUM
|
|
Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| B4-0687 | Tablet | Aquaclav 625 Tablets TAB 500 mg; 125 mg 2 x 7's (in Alu-Alu blisters) | Film-coated tablet. White coloured, capsule shaped, biconvex, both side plain film coated tablets | 21/12/2023 |
| B4-3287 | Powder for suspension | Aquaclav Suspension PWD_F_SOL 200 mg/5 mL; 28.5 mg/5 mL 100 mL (in HDPE white bottle) | Powder for Oral Suspension. White to off white granular powder, which becomes white coloured suspension on reconstitution with water | 26/08/2021 |
| B4-6857 | Tablet | Aquaclav 1 G Tablets TAB 875 mg; 125 mg 2 x 7's (in Alu-Alu blisters) | Film coated tablet | 27/03/2024 |
| B4-6858 | Tablet | Aquaclav 375 mg Tablets TAB 250 mg; 125 mg 2 x 7's; 2 x 10's (in blisters) | Film coated tablet | 27/03/2024 |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| J01CR02 | Amoxicillin and enzyme inhibitor | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01C Beta-lactam antibacterials, penicillins → J01CR Combinations of penicillins, incl. beta-lactamase inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | B4-0687, B4-3287, B4-6857, B4-6858 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.